Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Filter By:

Search by Keyword (disease, investigator, treatment name):

M6620 and Irinotecan Hydrochloride in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Miscellaneous

This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Disease Sites: Miscellaneous

Phase: I

Investigator: Davis, Elizabeth

NCTID: NCT02595931

Protocol No: VICCPHI16154ET-CT

Learn More